Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma (H-27371)
A controlled, parallel-group, randomized, open-label study to evaluate two lenalidomide dose regimes when used in combination with lose dose dexamethasone for treatment of subjects with relapsed multiple myeloma (H-27371)
This is a multi-center, controlled, open-label, randomized study intended to select a tolerable dose regimen with acceptable efficacy of Lenalidomide, when used in combination with Dexamethasone. Subjects will receive either oral Lenalidomide 25 mg or Lenalidomide 15 mg once daily for days 1-21 out of a 28 day cycle. The subjects must have relapsed or refractory disease requiring 2nd or 3rd line treatment. The clinical trial is currently being offered at the Michael E. DeBakey Veterans Affairs Medical Center.
For more information: http://www.clinicaltrials.gov/ct2/show/NCT01380106